New drugs and dosage forms

June 2004
American Journal of Health-System Pharmacy;6/1/2004, Vol. 61 Issue 11, p1092
Academic Journal
This article presents information regarding new drugs and their dosage forms. It reports that the pharmaceutical company, Mayne Corp. acquired the drug product "Multivitamins" for infusion, intended for use in total parenteral nutrition, from aaiPharma Inc. This is a pediatric formulation and is a lyophilized powder. The new nasal aerosol formulation "Triamcinolone acetonide," presented by Aventis Corp., contains hydrofluoroalkane, instead of a chloroflurcarbon, as the propellant. A new antiepileptic agent, "Zonisamide capsules," is acquired by pharmaceutical company, Eisai Corp. from Elan Corp.


Related Articles

  • INDUSTRY NEWS.  // Pharmaceutical Technology Europe;Mar2013, Vol. 25 Issue 3, p42 

    This section offers world news briefs relating to pharmaceutical companies, including additional investments of Patheon, Elan Corp. selling its shares of Alkermes and service expansion by AAIPharma.

  • New drugs and dosage forms.  // American Journal of Health-System Pharmacy;5/15/2005, Vol. 62 Issue 10, p1010 

    Reports development in pharmaceutical industry. Indication of Alendronate sodium and cholecalciferol tablets for the treatment of osteoporosis in postmenopausal women; Recommended dosage for galantamine hydrobromide.

  • Elan's Fire Sale Still Underway.  // Pharmaceutical Executive;Jul2003, Vol. 23 Issue 7, p19 

    Features the pharmaceutical company Elan in Great Britain. Unavailability of the estimates on the price of Elan's drug delivery business; Agreements between King Pharmaceuticals Inc. and Elan; Enhancement of the company's ability to promote brand name prescription pharmaceutical products.

  • Smaller Is Better. McKinnie, Jason // Pharmaceutical Executive;Oct2006, Vol. 26 Issue 10, p76 

    The article focuses on the use of nanotechnology in drug delivery of pharmaceutical companies in the U.S. Elan Corp. PLC observes that nanobiotechnological drug delivery can reduce or eliminate revenue losses throughout the drug lifecycle. It is noted that the Insoluble Drug Delivery platform of...

  • Nanotechnology Advances in Drug Delivery. van Arnum, Patricia // Pharmaceutical Technology;Jun2007, Vol. 31 Issue 6, p48 

    The article discusses the advancement of nanotechnology by the drug delivery companies. They elevate nanotechnology in oral, injectible, transdermal and implantable systems to improve the bioavailability of the variety of drugs. Drug delivery companies like Elan Corp. PLC develops NanoCrystal...

  • Elan signs drug delivery deals.  // Medical Marketing & Media;Nov98, Vol. 33 Issue 11, p20 

    Reports that Elan Corp., a company that specializes in drug delivery systems, has increased its primary technology by buying Nanosystems LLC from Eastman Kodak Co. Amount of the acquisition; Information on Nanosystems; Amount received by Delsys Pharmaceutical Corp. from Elan to develop products...

  • Natural Excipients: Uses of Pharmaceutical Formulations. Patil, Priya S. // Copyright & New Media Law Newsletter;2014, Vol. 18 Issue 1, p21 

    With the increasing interest in polymers of natural origin, the pharmaceutical world has compliance to use most of them in their formulations. Pharmaceutical formulation development involves various components in addition to the active pharmaceutical ingredients. Nature has provided us a wide...

  • Biopharmaceutical Classification System in Invitro/ In-vivo Correlation: Concept and Development Strategies in Drug Delivery. Nainar, Sundaramoorthi; Rajiah, Kingston; Angamuthu, Santhosam; Prabakaran, D.; Kasibhatta, Ravisekhar // Tropical Journal of Pharmaceutical Research;Apr2012, Vol. 11 Issue 2, p319 

    Drug development is a very laborious and expensive process. One of the major reasons for failure during the clinical phases of drug development is inadequate pharmacokinetic data on the drug candidate. Therefore, it would be advantageous if the pharmacokinetic properties of drug candidates be...

  • AN APPROCH FOR DEVELOPMENT OF ORAL SUSTAINED RELEASE SUSPENSION. SOMPUR, C. K.; DOIJAD, R. C.; PATIL, S. M.; MASKE, A. P. // International Journal of Pharma & Bio Sciences;Apr-Jun2011, Vol. 2 Issue 2, pP.320 

    The scenario of pharmaceutical drug delivery is rapidly changing; conventional dosage forms are being replaced by new drug delivery system. One such drug delivery is sustained or controlled release drug delivery system the primary objective of sustained release drug delivery system is to ensure...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics